Sage Therapeutics Inc (SAGE)
11.32
-0.78
(-6.45%)
USD |
NASDAQ |
May 23, 16:00
11.30
-0.02
(-0.18%)
After-Hours: 20:00
Sage Therapeutics Enterprise Value: -35.75M for May 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 23, 2024 | -35.75M |
| May 22, 2024 | 11.19M |
| May 21, 2024 | 8.180M |
| May 20, 2024 | -44.18M |
| May 17, 2024 | -12.88M |
| May 16, 2024 | 5.773M |
| May 15, 2024 | -12.28M |
| May 14, 2024 | 4.569M |
| May 13, 2024 | 15.10M |
| May 10, 2024 | -0.8472M |
| May 09, 2024 | 25.63M |
| May 08, 2024 | 28.64M |
| May 07, 2024 | 64.15M |
| May 06, 2024 | 80.40M |
| May 03, 2024 | 121.92M |
| May 02, 2024 | 71.67M |
| May 01, 2024 | 82.20M |
| April 30, 2024 | 121.92M |
| April 29, 2024 | 136.37M |
| April 26, 2024 | 106.88M |
| April 25, 2024 | 100.26M |
| April 24, 2024 | 125.54M |
| April 23, 2024 | 62.34M |
| April 22, 2024 | 58.73M |
| April 19, 2024 | 85.21M |
| Date | Value |
|---|---|
| April 18, 2024 | 67.46M |
| April 17, 2024 | 39.47M |
| April 16, 2024 | 223.63M |
| April 15, 2024 | 204.98M |
| April 12, 2024 | 212.20M |
| April 11, 2024 | 280.20M |
| April 10, 2024 | 272.98M |
| April 09, 2024 | 277.19M |
| April 08, 2024 | 282.01M |
| April 05, 2024 | 271.18M |
| April 04, 2024 | 280.80M |
| April 03, 2024 | 315.11M |
| April 02, 2024 | 321.13M |
| April 01, 2024 | 360.24M |
| March 31, 2024 | 410.80M |
| March 28, 2024 | 373.22M |
| March 27, 2024 | 391.25M |
| March 26, 2024 | 366.00M |
| March 25, 2024 | 370.21M |
| March 22, 2024 | 402.07M |
| March 21, 2024 | 447.15M |
| March 20, 2024 | 429.72M |
| March 19, 2024 | 405.67M |
| March 18, 2024 | 411.08M |
| March 15, 2024 | 447.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-44.18M
Minimum
May 20 2024
8.541B
Maximum
Jul 12 2019
1.875B
Average
1.098B
Median
Enterprise Value Benchmarks
| Biogen Inc | 37.21B |
| Vanda Pharmaceuticals Inc | -108.39M |
| Ligand Pharmaceuticals Inc | 1.215B |
| ADMA Biologics Inc | 2.281B |
| Axsome Therapeutics Inc | 3.370B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -108.48M |
| Revenue (Quarterly) | 7.902M |
| Total Expenses (Quarterly) | 125.58M |
| EPS Diluted (Quarterly) | -1.80 |
| Gross Profit Margin (Quarterly) | 83.94% |
| Profit Margin (Quarterly) | -1.37K% |
| Earnings Yield | -74.12% |
| Normalized Earnings Yield | -69.19 |